Payment overview · 2025
General Payments
$120.60
1 reported records · 1 companies
Healthcare provider profile · identity verified
Mohammad H Baloch, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RALEIGH, NC · NPI 1295708592
Verified facts
What the public records show
CMS Open Payments records show Mohammad H Baloch, MD received $120.60 in general payments during 2025 across 1 reported records.
GlaxoSmithKline, LLC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $120.60 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $120.60 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $120.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 538 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 437 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 269 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 59 |
| Metformin Hcl | Metformin Hcl | 236 | 59 |
| Omeprazole | Omeprazole | 184 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 183 | 46 |
| Pioglitazone Hcl | Pioglitazone Hcl | 167 | 42 |
| Meloxicam | Meloxicam | 165 | 43 |
| Alendronate Sodium | Alendronate Sodium | 164 | 32 |
| Gabapentin | Gabapentin | 152 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 43 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 137 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 127 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 126 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 34 |
| Lisinopril | Lisinopril | 109 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 108 | 29 |
| Allopurinol | Allopurinol | 106 | 24 |
| Losartan Potassium | Losartan Potassium | 92 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 18 |
| Potassium Chloride | Potassium Chloride | 82 | 24 |
| Metformin Hcl Er | Metformin Hcl | 80 | 22 |
| Eliquis | Apixaban | 79 | 20 |
| Linzess | Linaclotide | 74 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 22 |
| Trazodone Hcl | Trazodone Hcl | 73 | 22 |
| Carvedilol | Carvedilol | 72 | 22 |
| Farxiga | Dapagliflozin Propanediol | 70 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 22 |
| Carbamazepine | Carbamazepine | 60 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 60 | 15 |
| Furosemide | Furosemide | 59 | 14 |
| Spironolactone | Spironolactone | 59 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 57 | 16 |
| Montelukast Sodium | Montelukast Sodium | 56 | 12 |
| Jardiance | Empagliflozin | 55 | 15 |
| Simvastatin | Simvastatin | 55 | 16 |
| Finasteride | Finasteride | 54 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 18 |
| Glipizide | Glipizide | 48 | 13 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 48 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 14 |
| Ezetimibe | Ezetimibe | 45 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 21 |
| Chlorthalidone | Chlorthalidone | 43 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | 11 |
| Januvia | Sitagliptin Phosphate | 37 | 13 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | 11 |
| Indapamide | Indapamide | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Clonidine Hcl Er | Clonidine Hcl | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Colchicine | Colchicine | 26 | 11 |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 15 |
| Lactulose | Lactulose | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Ibu | Ibuprofen | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 22 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Piroxicam | Piroxicam | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Azithromycin | Azithromycin | 17 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Risperidone Odt | Risperidone | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 11 | suppressed |
| Valtoco | Diazepam | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $120.60 · 1 records | GlaxoSmithKline, LLC. | AREXVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error